Method for selective inactivation of viral replication
AssigneeRigel Pharmaceuticals, Inc.
InventorsVincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
Life of this patent
Estimating the term…
Abstract
Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
Claims20
A method of assaying for a potential antiviral agent comprising:
- a) providing a eukaryotic cell comprising a nucleic acid construct comprising:
- i) a viral internal ribosome entry site (IRES);
- and
- ii) a reporter gene encoding a reporter protein, wherein said IRES is operably linked to said reporter gene;
- b) adding an agent to be tested to said cell;
- and
- c) determining the presence of the reporter protein, wherein said agent is a potentially useful antiviral agent if the amount of the reporter protein produced in the presence of the test agent is less than an amount of reporter protein produced in the absence of said test agent.
A method of assaying for a potential antiviral agent comprising:
- a) providing protein translation mixture comprising:
- i) a nucleic acid construct comprising:
- 1) a viral internal ribosome entry site (IRES), wherein said IRES is from a virus selected from the group consisting of an enterovirus, a rhinovirus, an apthovirus, a hepatitis A virus, a hepatitis B virus and a hepatitis C virus;
- and
- 2) a reporter gene encoding a reporter protein, wherein said IRES is operably linked to said reporter gene;
- ii) ribosomes;
- iii) an agent to be tested;
- b) incubating the components of said mixture under conditions effective to produce said reporter protein;
- and
- c) determining the presence of the reporter protein, wherein said agent is a potentially useful antiviral agent if the amount of the reporter protein produced in the presence of the test agent is less than an amount of reporter protein produced in the absence of said test agent.
A method of assaying for a potential antiviral agent comprising:
- a) providing a protein translation mixture comprising:
- i) a nucleic acid construct comprising:
- 1) a vital internal ribosome entry site (IRES);
- 2) a reporter gene encoding a reporter protein, wherein said IRES is operably linked to said reporter gene;
- and
- 3) a eukaryotic mRNA-5′-terminal cap and untranslated region (UTR) at the 5′ end of the construct;
- ii) ribosomes;
- iii) an agent to be tested;
- b) incubating the components of said mixture under conditions effective to produce the reporter protein;
- and
- c) determining the presence of the reporter protein, wherein said agent is a potentially useful antiviral agent if the amount of the reporter protein produced in the presence of the test agent is less than an amount of reporter protein produced in the absence of said test agent.
Dependencies are inferred from the claim text.